source
- Tiziana's lower-dose foralumab cuts neuroinflammation in SPMS, but higher dose failsTiziana Life Sciences reported that its intranasal anti‑CD3 antibody, foralumab, lowered a neuroinflammation biomarker in patients with non‑active secondary progressive multiple sclerosis when give…
- FDA places Bright Minds seizure drug BMB-101 on partial hold over mouse toxicity, shares plungeThe U.S. Food and Drug Administration issued a partial clinical hold on BMB-101, an experimental seizure treatment from Bright Minds Biosciences, after regulators identified toxicity concerns in pr…